Study sheds light on progress and gaps in hepatitis C clearance cascade

Medical Life Sciences
Jul 04, 2023

Study sheds light on progress and gaps in hepatitis C clearance cascade


In the recent Centres for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR), researchers described the hepatitis C virus (HCV) elimination cascade during the direct-acting antivirals (DAA) era between January 1 2013 and December 31 2022.

Background

Hepatitis C is a serious health concern in the United States, causing advanced liver disease, cancer, and death. A brief course of orally administered and well-tolerated directly acting antivirals is advised for HCV-infected individuals to combat this.

A nationwide program to eradicate HCV was put forth with the Viral Hepatitis Nationwide Strategic Plan calling for 80.0% of individuals to eliminate HCV by 2030.

Establishing a comprehensive nationwide HCV infection cascade is difficult due to the scarcity of one data source that could describe all the steps.